diarrhea in Extend­ed release study [Outliers]

posted by Researcher101 – Egypt, 2020-09-23 23:53 (1743 d 17:05 ago) – Posting: # 21935
Views: 3,471

Dear All, I'm asking if I have a study on product containing two actives (one IR and the other extended release) and a participant had a diarrhea after Tmax of the IR active and through the Tmax of the XR active. should I exclude the participant from the study? or include him in the XR active statistical calculation and exclude in the IR? :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,426 posts in 4,929 threads, 1,682 registered users;
57 visitors (0 registered, 57 guests [including 10 identified bots]).
Forum time: 16:59 CEST (Europe/Vienna)

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5